<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sebaceous carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sebaceous carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sebaceous carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia Tai, MB, BS, DMRT, FRCR, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Laurin Council, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Stern, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H65628295"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sebaceous carcinoma is a rare, malignant tumor of the sebaceous glands [<a href="#rid1">1</a>]. It can occur in any body site where sebaceous glands are present but is most commonly found in the head and neck region, particularly in the periocular area [<a href="#rid2">2</a>]. Sebaceous carcinoma of the eyelid  (<a class="graphic graphic_picture graphicRef70403" href="/d/graphic/70403.html" rel="external">picture 1</a>) may be mistaken for inflammatory lesions, such as chalazion or blepharoconjunctivitis, resulting in a delayed diagnosis and poorer prognosis [<a href="#rid3">3</a>].</p><p>Sebaceous carcinomas can occur sporadically or may be associated with Muir-Torre syndrome, a variant of the hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome) characterized by single or multiple sebaceous neoplasms, keratoacanthomas, and internal malignancy (particularly malignancy of the gastrointestinal or genitourinary system) [<a href="#rid4">4,5</a>].</p><p>This topic will review the pathogenesis, clinical presentation, diagnosis, and treatment of sebaceous carcinoma. Muir-Torre syndrome and Lynch syndrome are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98605.html" rel="external">"Muir-Torre syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management"</a>.)</p><p></p><p class="headingAnchor" id="H65628301"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Sebaceous carcinoma is a rare tumor, with an estimated incidence rate of approximately 1 to 2 per 1,000,000 per year [<a href="#rid2">2,4,6-8</a>]. However, sebaceous carcinoma is the most common eyelid malignancy after basal cell carcinoma and squamous cell carcinoma [<a href="#rid9">9,10</a>]. In a review of the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2012 that identified 2201 cases of sebaceous carcinoma, the incidence rate among White Americans was almost three times higher than among Black Americans and other ethnic groups, and more than 98 percent of cases were older than 40 years, with a peak incidence between the ages of 60 to 79 years [<a href="#rid8">8</a>]. Outcomes of White and Asian patients with sebaceous carcinoma are similar, but Black individuals have a markedly lower five-year relative survival rate compared with White patients [<a href="#rid11">11</a>]. Finally, sebaceous carcinoma is exceedingly rare in children, with only a few cases reported [<a href="#rid12">12,13</a>].</p><p>In a small subgroup of patients, typically younger than 60 years [<a href="#rid14">14</a>], sebaceous carcinoma may be a marker of Muir-Torre syndrome, an autosomal dominant disorder considered a variant of hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome). In an analysis of the National Cancer Institute SEER registry from 2000 to 2012 including 3299 cases of sebaceous carcinoma, 64 patients (1.9 percent) had Muir-Torre syndrome [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/98605.html" rel="external">"Muir-Torre syndrome"</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H25153541"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Ocular sebaceous carcinomas arise from the meibomian (tarsal), Zeis (eyelash), or sebaceous glands of the eyelid and caruncle. There are several reports of sebaceous carcinoma arising within a nevus sebaceous [<a href="#rid16">16</a>]. The origin of extraocular sebaceous carcinoma is less clear. The observation of sebaceous carcinoma in association with actinic keratosis or Bowen disease suggests that extraocular sebaceous carcinoma may originate from a pre-existing intraepidermal neoplasia or that ultraviolet radiation plays a role in the pathogenesis of some of these tumors in sun-exposed areas [<a href="#rid17">17-19</a>].</p><p>The molecular pathogenesis of sebaceous carcinoma is incompletely understood [<a href="#rid20">20</a>]. Loss of expression of mismatch repair genes <em>MSH2</em>, <em>MSH6</em>, or <em>MLH1</em> and microsatellite instability (MSI) are seen in sebaceous carcinomas associated with Muir-Torre syndrome as well as in other cancers associated with the hereditary Lynch syndrome [<a href="#rid21">21</a>]. Loss of expression of <em>MSH2</em> and MSI have also been detected in sebaceous carcinomas in organ transplant recipients, suggesting that immunosuppression may unmask a Muir-Torre phenotype [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/98605.html" rel="external">"Muir-Torre syndrome"</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genetics'</a>.)</p><p>Sporadic sebaceous carcinomas may show somatic variants in the mismatch repair genes <em>MLH1</em> and <em>MSH2</em> as well as in <em>TP53</em> and other genes potentially involved in tumorigenesis [<a href="#rid24">24-26</a>]. A whole-exome sequencing study of 32 sebaceous carcinomas identified three genetically distinct groups of sebaceous carcinomas (based on the predominant somatic mutation pattern): tumors harboring <em>TP53</em> ultraviolet-damage signature variants with high numbers of CC &gt; TT dinucleotide transitions (10 of 32), tumors harboring MSI signatures (9 of 32), and a group of 13 paucimutational tumors with no dominant mutational signature, of which six showed truncating variants in the <em>ZNF750</em> transcription factor gene (an epidermal differentiation regulator) [<a href="#rid24">24</a>].</p><p>Hypermethylation of the <em>CDKN2A</em> promoter region has also been found with high frequency in periocular sebaceous carcinoma occurring at a younger age [<a href="#rid27">27</a>].</p><p>Studies have suggested a role for the Wnt/beta-catenin (a 92-kDa molecule involved in cell-cell adhesion in adherens junctions) pathway and the downstream target lymphoid enhancer binding factor-1 (LEF-1) in the pathogenesis of sebaceous carcinoma, irrespective of the microsatellite status [<a href="#rid21">21,28,29</a>].</p><p>Trophoblast cell surface antigen 2 (TROP2), a cell-surface glycoprotein involved in several intracellular signaling pathways, is highly expressed in various human cancers, including basal cell carcinoma and squamous cell carcinoma of the skin. Strong expression of TROP2 has been detected in sebaceous carcinoma and sweat gland carcinoma, suggesting a potential therapeutic role for <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, an antibody-drug conjugate that targets the cell-surface antigen TROP2 [<a href="#rid30">30</a>].</p><p>Immunohistochemical studies have demonstrated strong and frequent expression of NECTIN4 and TROP2 in sebaceous carcinoma, suggesting that NECTIN4- and TROP2-targeted antibody-drug conjugates, such as <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> and <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, respectively, may have efficacy in systemic disease as well [<a href="#rid30">30,31</a>]. Additionally, epidermal growth factor receptor (EGFR) is expressed in most cases of sebaceous carcinoma and could be a therapeutic target in metastatic cases [<a href="#rid32">32</a>].</p><p>As with other nonmelanoma skin cancers, the development of sebaceous carcinoma has also been described in a patient on <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> therapy [<a href="#rid33">33</a>]. Additionally, immunosuppression significantly increases one's risk for the development of sebaceous carcinoma [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H65628321"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Sebaceous carcinoma typically presents as a firm, gradually enlarging subcutaneous nodule  (<a class="graphic graphic_picture graphicRef98669" href="/d/graphic/98669.html" rel="external">picture 2</a>). Approximately 80 percent of cases occur in the skin of the head or neck, and approximately 40 percent involve the eyelids [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H256433439"><span class="h2">Eyelid sebaceous carcinoma</span><span class="headingEndMark"> — </span>Eyelid sebaceous carcinoma is the third most common malignant tumor of the eyelid after basal cell carcinoma and squamous cell carcinoma [<a href="#rid35">35</a>]. It typically presents in older patients as a painless, rounded nodule, most often located on the upper eyelid. This is in contrast to periocular basal cell carcinoma and squamous cell carcinoma, which are most commonly located on the lower lid. Occasionally, the lesion can be inflamed and painful and may be clinically mistaken for a chalazion  (<a class="graphic graphic_picture graphicRef81651" href="/d/graphic/81651.html" rel="external">picture 4B</a>), leading to a delay in diagnosis and appropriate treatment. A lesion with visible, superficial vessels that alters the eyelid margin and the eyelash line should raise suspicion of sebaceous carcinoma  (<a class="graphic graphic_picture graphicRef70403" href="/d/graphic/70403.html" rel="external">picture 1</a>). The second most common presentation is a diffuse, unilateral thickening of the eyelid accompanied by an inflammatory reaction that simulates blepharoconjunctivitis [<a href="#rid36">36</a>].</p><p>Eyelid sebaceous carcinoma may spread locally to involve the palpebral and bulbar conjunctiva and cornea. Unilateral signs of blepharoconjunctivitis, with thickening of the eyelids, loss of cilia, diffuse erythema, thickening of the conjunctiva, and superficial vascularity of the cornea, suggest epithelial involvement due to pagetoid spread of the tumor [<a href="#rid37">37</a>]. Isolated primary sebaceous gland carcinoma of the bulbar conjunctiva has been described, although the lesion typically begins on the eyelid margin and palpebral conjunctiva [<a href="#rid38">38</a>]. In advanced cases, the tumor can invade the orbital soft tissue, bone, and intracranial cavity.</p><p class="headingAnchor" id="H256433445"><span class="h2">Extraocular sebaceous carcinoma</span><span class="headingEndMark"> — </span>Extraocular sebaceous carcinoma usually presents as a yellowish-tan nodule, often ulcerated, located on the head and neck in most cases or, less frequently, on the trunk or extremities. Rarely, sebaceous carcinomas may develop in extracutaneous sites, such as the parotid gland, nasal cavity, breast, large bowel, ovary, and prostate [<a href="#rid39">39-41</a>].</p><p class="headingAnchor" id="H71756451"><span class="h2">Metastasis</span><span class="headingEndMark"> — </span>Metastasis occurs in approximately 12 percent of patients with eyelid sebaceous carcinoma, with an average time to metastasis of 20.5 months [<a href="#rid35">35</a>]. Among patients with extraocular sebaceous carcinoma from registries of the Surveillance, Epidemiology, and End Results (SEER) database, the rate of nodal or distant metastases was 1.4 percent [<a href="#rid42">42</a>]. Regional lymph nodes are the most common site of metastasis [<a href="#rid43">43</a>]. Tumors located on the upper eyelid tend to metastasize to preauricular and parotid nodes; tumors of the lower eyelid tend to metastasize to submandibular and cervical nodes [<a href="#rid37">37</a>]. Distant metastasis may involve the parotid gland, liver, lung, and bone [<a href="#rid43">43-45</a>].</p><p class="headingAnchor" id="H65628339"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of sebaceous carcinoma is suspected in older patients with a history of recalcitrant chalazion or unilateral blepharoconjunctivitis that does not respond to standard treatment  (<a class="graphic graphic_picture graphicRef70403" href="/d/graphic/70403.html" rel="external">picture 1</a>). Clinical misdiagnosis and failure to perform a biopsy results in delay in diagnosis and poor outcome [<a href="#rid46">46</a>]. The average diagnostic delay is approximately 15 months [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H45109514"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>An excisional biopsy or a deep incisional biopsy is required to establish the diagnosis [<a href="#rid46">46</a>]. Immunohistochemistry is helpful to diagnose sebaceous carcinoma with indeterminate features and to distinguish poorly differentiated sebaceous carcinoma from basal cell carcinoma and squamous cell carcinoma. (See <a class="local">'Histopathology'</a> below.)</p><p class="headingAnchor" id="H81298532"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Routine histopathologic examination with hematoxylin and eosin shows neoplastic cells (basaloid, basosquamous, and epidermoid) with various degrees of differentiation arranged in lobules or sheets of cells separated by a fibrovascular stroma  (<a class="graphic graphic_picture graphicRef98304" href="/d/graphic/98304.html" rel="external">picture 3</a>) [<a href="#rid9">9</a>]. In eyelid lesions, upward migration and spreading to the surface epidermis or conjunctiva in a pagetoid pattern is often seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated tumors may contain sebocyte-like cells with vacuolated, foamy cytoplasm. In frozen specimens, an Oil Red O stain can demonstrate intracytoplasmic lipid [<a href="#rid47">47</a>]. Differential diagnoses are multilineage adnexal tumors with partly sebaceous differentiation, sebaceous changes as a component of benign cystic lesions or epidermal tumors, clear cell squamous cell carcinoma, nevus sebaceous, and the commonly encountered sebaceous hyperplasia [<a href="#rid46">46,48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated lesions usually show both a sebaceous and squamous differentiation and may be confused with squamous cell carcinoma. Nuclear pleomorphism, prominent nucleoli, and mitotic figures are usually present.</p><p></p><p class="headingAnchor" id="H25153645"><span class="h2">Immunohistochemistry</span><span class="headingEndMark"> — </span>Positive immunostaining with nuclear factor XIIIa (clone AC-1A1 mouse monoclonal), epithelial membrane antigen (EMA), adipose differentiation-related protein (adipophilin) and perilipin, androgen receptor, and cytokeratin AE1/AE3 antibody confirms sebaceous differentiation and differentiates sebaceous carcinoma from basal cell carcinoma and squamous cell carcinoma [<a href="#rid46">46,50-52</a>].</p><p>Markers that are typically negative in sebaceous carcinoma include carcinoembryonic antigen, S100, HMB45, SOX10, CD5, GCDFP-15, D2-40, and Ber-EP4 (occasionally positive) [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H25682815"><span class="h2">Screening for Muir-Torre syndrome</span><span class="headingEndMark"> — </span>Although most sebaceous carcinomas occur sporadically, in a small subgroup of patients, these tumors are a marker of Muir-Torre syndrome, an autosomal dominant disorder considered a variant of hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome). Muir-Torre syndrome is characterized by the development of sebaceous tumors in association with visceral neoplasms [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/98605.html" rel="external">"Muir-Torre syndrome"</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p>Based on recommendations in published expert guidelines [<a href="#rid46">46</a>], genetic testing for Muir-Torre syndrome is recommended in patients with <strong>extraocular</strong> sebaceous carcinoma and/or a Mayo Muir-Torre syndrome overall risk score ≥2 [<a href="#rid54">54</a>]. The Mayo Muir-Torre syndrome score is calculated by adding the scores associated with the following four variables:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;60 years at first presentation of sebaceous carcinoma (score = 1)</p><p class="bulletIndent1"><span class="glyph">●</span>≥2 sebaceous tumors (score = 2)</p><p class="bulletIndent1"><span class="glyph">●</span>Personal history of any Lynch syndrome-related cancers (score = 1)</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of any Lynch syndrome-related cancers, such as colorectal cancer and endometrial cancer (score = 1)</p><p></p><p>For patients with sebaceous carcinoma and suspected Muir-Torre syndrome who do not fulfill the Mayo Muir-Torre syndrome clinical criteria (eg, patients &lt;60 years with a first extraocular sebaceous carcinoma [score = 1]), immunohistochemical tumor testing for loss of mismatch repair proteins is appropriate to identify patients who are candidates for genetic testing [<a href="#rid55">55,56</a>]. (See  <a class="medical medical_review" href="/d/html/98605.html" rel="external">"Muir-Torre syndrome", section on 'Tumor testing'</a>.)</p><p class="headingAnchor" id="H65628346"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of sebaceous carcinoma includes several benign and malignant conditions, including [<a href="#rid36">36,47,57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory lesions</strong> – Sebaceous carcinoma may mimic chalazion  (<a class="graphic graphic_picture graphicRef80892 graphicRef81651 graphicRef62030" href="/d/graphic/80892.html" rel="external">picture 4A-C</a>), blepharoconjunctivitis, or keratoconjunctivitis. Inflammatory eye conditions that are unilateral and fail to respond to standard treatment should be biopsied and sent for histopathologic examination. Additionally, sebaceous carcinoma masquerading as orbital cellulitis has been reported [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/6898.html" rel="external">"Eyelid lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign sebaceous neoplasms</strong> – Benign sebaceous neoplasms (eg, sebaceous adenoma  (<a class="graphic graphic_picture graphicRef98399" href="/d/graphic/98399.html" rel="external">picture 5</a>), sebaceoma) are not common in the periocular region. The finding of sebaceous differentiation in an eyelid lesion should raise the suspicion of malignancy. (See  <a class="medical medical_review" href="/d/html/16910.html" rel="external">"Cutaneous adnexal tumors", section on 'Tumors with sebaceous differentiation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basal cell carcinoma</strong> – Nodular basal cell carcinoma is more common on the lower eyelid but may occur on the upper eyelid  (<a class="graphic graphic_picture graphicRef117542" href="/d/graphic/117542.html" rel="external">picture 6</a>) and tends to ulcerate at an early stage, whereas ulceration is uncommon in sebaceous carcinoma. The morpheaform variant of basal cell carcinoma may also simulate sebaceous carcinoma, but conjunctival involvement is uncommon.</p><p></p><p class="bulletIndent1">Immunohistochemical staining for epithelial membrane antigen (EMA) and adipophilin are negative in basal cell carcinoma but positive in nearly all sebaceous carcinomas [<a href="#rid50">50,51</a>]. Ber-EP4 is typically positive in basal cell carcinoma but may be positive or negative in sebaceous carcinoma. (See  <a class="medical medical_review" href="/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell carcinoma</strong> – Squamous cell carcinoma may occur on the upper eyelid, and clear cell squamous cell carcinoma can mimic sebaceous carcinoma [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">Immunohistochemical staining for EMA may be positive in squamous cell carcinoma, but adipophilin and androgen receptor are consistently negative [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Merkel cell carcinoma </strong>– Merkel cell carcinoma may present as a red lesion on the eyelid. Histologic examination can clarify the diagnosis. (See  <a class="medical medical_review" href="/d/html/7623.html" rel="external">"Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma"</a>.)</p><p></p><p>Cutaneous clear cell tumors, including epidermoid carcinoma with sebaceous differentiation, clear cell acanthoma, trichilemmoma, and balloon cell melanoma, may be confused histologically with sebaceous carcinoma.</p><p class="headingAnchor" id="H25153657"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The staging of periocular sebaceous carcinomas is performed according to the staging system for eyelid carcinoma outlined in the eighth edition of the American Joint Committee on Cancer Staging Manual  (<a class="graphic graphic_table graphicRef129566" href="/d/graphic/129566.html" rel="external">table 1</a>) [<a href="#rid59">59-63</a>]. Extraocular sebaceous carcinoma in the head and neck region shares the same staging system as cutaneous squamous cell carcinoma of the head and neck  (<a class="graphic graphic_table graphicRef110946" href="/d/graphic/110946.html" rel="external">table 2</a>) [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1798099854"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Patients diagnosed with sebaceous carcinoma should receive a careful examination of the tumor site to assess the clinical extent of the tumor. Palpation of the regional lymph nodes should be performed to assess for enlarged lymph nodes that may indicate regional metastasis.</p><p class="headingAnchor" id="H1550640548"><span class="h2">Ophthalmologic examination</span><span class="headingEndMark"> — </span>Patients with sebaceous carcinoma of the eyelids should be referred to an ophthalmologist for the evaluation of conjunctival involvement. Slit lamp biomicroscopy and conjunctival map biopsies are used to determine the presence and extent of intraepithelial disease [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3198718027"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Ultrasonography or computerized tomography (CT) scan of regional lymph nodes is indicated to complete tumor staging for larger or more aggressive tumors [<a href="#rid46">46,64</a>]. In patients with large tumors located in the periorbital area, CT or magnetic resonance imaging (MRI) should be performed to evaluate for invasion of orbital soft tissue, bone, or intracranial cavity. Positron emission tomography (PET) scan should be considered for patients with confirmed nodal metastasis or Muir-Torre syndrome [<a href="#rid46">46,65</a>].</p><p class="headingAnchor" id="H1395472425"><span class="h2">Sentinel lymph node biopsy</span><span class="headingEndMark"> — </span>Sentinel lymph node biopsy (SLNB) is generally <strong>not</strong> indicated for extraocular sebaceous carcinoma, which is associated with a low risk of nodal and distant metastases [<a href="#rid66">66</a>]. Among 867 patients with extraocular sebaceous carcinoma from the National Cancer Institute's registries of the Surveillance, Epidemiology, and End Results (SEER) database, the rate of nodal or distant metastases was 1.4 percent [<a href="#rid42">42</a>]. However, SLNB along with imaging may be indicated for complete tumor staging of larger or more aggressive periocular tumors (ie, eyelid tumor stage T2c or higher) [<a href="#rid42">42,46,67,68</a>].</p><p>Data on the rate of positive sentinel lymph node are sparse. In a series of 100 patients with periocular sebaceous carcinoma, 5 of 30 patients (16.7 percent) who underwent SLNB had positive sentinel lymph node, and two were false negative [<a href="#rid67">67</a>]. A review of the United States National Cancer Database revealed that SLNB was performed in 149 of 1320 patients with periocular and extraocular seborrheic carcinoma (10.7 percent) [<a href="#rid68">68</a>]. A positive SLNB was found in 11 cases (7.4 percent).<em> </em>The benefit of SLNB on disease-specific survival is unknown.</p><p class="headingAnchor" id="H65628333"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3803238920"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>Sebaceous carcinoma is a locally aggressive tumor that can metastasize to locoregional lymph nodes and distant sites. The primary goal of management is the complete surgical removal of the tumor. Local recurrence is due to incomplete excision in most cases (due to the multifocal nature of the tumor), with discontinuous intraepithelial involvement and pagetoid spread of malignant sebocytes along the conjunctiva [<a href="#rid35">35</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>For periocular lesions, additional management goals include the identification and treatment of subclinical intraepithelial neoplasia, vision salvage, avoidance of exenteration, and acceptable cosmetic outcome [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H25153691"><span class="h2">Local disease</span></p><p class="headingAnchor" id="H81299100"><span class="h3">Surgical treatment</span><span class="headingEndMark"> — </span>Surgical excision with peripheral and deep en face margin assessment (PDEMA), also called excision with complete circumferential peripheral and deep margin assessment (CCPDMA), or Mohs micrographic surgery (if available) are the first-line treatments for sebaceous carcinoma of the head and neck region (including eyelid tumors) [<a href="#rid2">2,36,69</a>]. For extraocular sebaceous carcinoma, if Mohs surgery or CCPDMA are not available, wide local excision (WLE) with peripheral 1 cm margin down to the deep fascial plane can be performed [<a href="#rid46">46</a>].</p><p>Because the interpretation of frozen sections may be problematic (eg, in differentiating vacuolating cytoplasm from freezing artifacts in conjunctival margins), some experts advocate the use of frozen <strong>and</strong> permanent paraffin-embedded sections for margin control [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/13708.html" rel="external">"Mohs surgery"</a>.)</p><p>Studies on large case series indicate that Mohs surgery is associated with lower rates of local recurrence and better overall survival than WLE:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 1265 patients with sebaceous carcinoma from the United States National Cancer Database of whom 234 were treated with Mohs surgery and 1031 were treated with WLE, patients who underwent Mohs surgery had a longer overall five-year survival than those who underwent surgical excision (75 versus 66 percent, respectively) [<a href="#rid71">71</a>]. On multivariable regression analysis, Mohs surgery was associated with better overall survival than surgical excision after adjusting for other prognostic factors, such as tumor size and clinical stage (hazard ratio [HR] 0.70, 95% CI 0.50-0.99).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, cohort study that included 360 patients with eyelid sebaceous carcinoma (115 patients [32 percent] treated with Mohs surgery and 245 patients [68 percent] treated with WLE), the local recurrence rate was lower in the Mohs surgery group than in the WLE group (15.7 versus 39.6 percent, respectively) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 554 patients with localized sebaceous carcinoma from the United States National Cancer Database who underwent WLE (n = 243) or Mohs surgery (n = 311) between 2004 and 2015 showed a similar overall survival at five years for the two groups (65.8 and 61.4 percent, respectively) [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H1015502703"><span class="h3">Conjunctival involvement</span><span class="headingEndMark"> — </span>Conjunctival epithelial involvement may be treated with surgical resection, cryotherapy, and/or topical <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> [<a href="#rid37">37,46</a>]. Posterior lamellar resection, a surgical technique that entails removing the entire tarsal plate and palpebral conjunctiva, has been described as having lower morbidity and lower risk of metastases than lumpectomy [<a href="#rid74">74</a>]. For tumors with extensive intraorbital involvement, surgical management may include orbital exenteration.</p><p class="headingAnchor" id="H264503127"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy (RT) may be used as primary treatment for both periocular and extraocular tumors in patients who are not surgical candidates and in patients who have tumors or nodal metastases that are surgically unresectable [<a href="#rid46">46</a>]. Postsurgical adjuvant RT is used for tumors excised with positive margin or tumors with histopathologic evidence of perineural invasion. RT is also used for palliation or after resection of local recurrence.</p><p>The general principles of RT for skin cancer also apply to sebaceous carcinoma, with the higher dose of up to 66.6 to 70 Gy applied to larger lesions. However, high doses to the upper eyelid are associated with severe complications, including keratitis. RT doses for definitive treatment of periocular sebaceous carcinoma are 56 to 70 Gy in two Gy fractions, with margins varying depending on the surrounding sensitive structures [<a href="#rid46">46</a>]. A total of 50 to 70 Gy in two Gy fractions with 2 cm margin has been used in case reports of extraocular sebaceous carcinoma [<a href="#rid75">75</a>]. Postoperative adjuvant RT doses of 50 to 60 Gy are recommended for perineural invasion.</p><p>Radiation oncologists should use a smaller fraction size to decrease long-term complications and improve cosmetic outcome, especially in areas with poor blood supply. An orthovoltage machine (if available) is preferred to electron treatment because the RT fields are smaller due to a narrow penumbra, and shielding is easier (a 6 MeV electron beam produces bremsstrahlung radiation, and the cornea receives a small RT dose behind the eye shield). Moreover, it is less expensive (linear accelerator machines required to produce electrons are more costly), has a higher relative biologic effectiveness, and provides better local control. The electron dose should be higher by 10 percent to be as effective as orthovoltage.</p><p>Eye drops with a local anesthetic and steroid should be applied before inserting the eye shield. The patient should wear an eye patch one to two hours after RT each day.</p><p>A few small studies have reported the use of RT as the primary treatment for sebaceous carcinoma of the eyelid [<a href="#rid76">76-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, eight patients with eyelid sebaceous carcinoma were treated with high-dose rate interstitial brachytherapy (a total of 39 Gy in six fractions in six days) as initial treatment [<a href="#rid76">76</a>]. All patients showed a complete response, with a five-year, disease-free survival rate of 57 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study that included 23 patients with eyelid carcinoma, 16 patients with histologically confirmed sebaceous carcinoma were treated with a median dose of 60 Gy (range 50 to 66.6 Gy) delivered in 18 to 37 fractions [<a href="#rid77">77</a>]. The reported five-year overall and local progression-free rates were 80 and 93 percent, respectively.</p><p></p><p>Plaque brachytherapy (50 Gy) instead of exenteration has been used for tumors involving the lacrimal gland or orbit [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H409583220"><span class="h4">Contraindications and adverse effects</span><span class="headingEndMark"> — </span>Contraindications for RT include previous RT in the same area and genetic conditions predisposed to skin malignancies (eg, xeroderma pigmentosum). RT should be used with caution in patients with connective tissue diseases.</p><p>Common acute side effects of RT are conjunctivitis (from local anesthetic eye drops and RT), eyelid erythema and edema, and conjunctival congestion and chemosis. Long-term side effects of RT include loss of eyelashes; deformities of the eyelid, including ectropion or entropion (eyelashes growing outside and inside, respectively); dry eye due to RT dose to lacrimal gland; keratitis; epiphora or tearing due to fibrosis of lacrimal duct; and cataract. Radiation-induced cataract has been reported in 3 out of 23 patients in one series [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H1104273"><span class="h2">Adjuvant therapies</span><span class="headingEndMark"> — </span>Cryotherapy, topical <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, and RT have been used in small series of patients as postsurgical adjuvant therapy for sebaceous carcinoma of the eyelid showing pagetoid spread to the conjunctiva and/or regional lymph node involvement:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryotherapy</strong> – Cryotherapy is frequently used as an adjunctive treatment after surgical excision of sebaceous carcinoma of the eyelid, particularly for the management of pagetoid invasion of conjunctiva [<a href="#rid81">81</a>]. However, cryotherapy may be associated with serious adverse effects, including symblepharon and corneal erosions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>mitomycin</strong> – Topical <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> has been used in a small number of patients for the treatment of pagetoid spread to the conjunctiva and cornea with varying results [<a href="#rid36">36,82-84</a>]. Complications of topical mitomycin treatment include persistent keratoconjunctivitis, epiphora secondary to punctal stenosis, allergic reaction, and limbal stem cell deficiency [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – The use of radiation therapy (RT) as an adjuvant therapy after surgery has been evaluated in a small, retrospective study of 13 patients with locally advanced tumors, 10 of whom had regional lymph node involvement [<a href="#rid86">86</a>]. A recurrence occurred in two of seven patients who had received adjuvant RT postoperatively and in five of six patients who did not receive RT.</p><p></p><p class="headingAnchor" id="H687035405"><span class="h2">Neoadjuvant therapies</span><span class="headingEndMark"> — </span>Successful use of neoadjuvant systemic chemotherapy with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> has been described in small case series of locally advanced eyelid tumors [<a href="#rid87">87,88</a>]. In a single case report of mismatch repair-deficient sebaceous carcinoma of bilateral eyelids, immunotherapy with the programmed death receptor-1 (PD-1) inhibitor <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (two doses of 400 mg six weeks apart) reduced tumor burden, allowing for a smaller defect post-Mohs surgery and better reconstructive outcome [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H25153752"><span class="h2">Nodal and distant metastatic disease</span><span class="headingEndMark"> — </span>The management of patients with metastatic sebaceous carcinoma should be discussed in a multidisciplinary tumor board with expertise in the treatment of such tumors. Data on the treatment of locoregional or distant metastasis of sebaceous carcinoma are limited to small case series and case reports [<a href="#rid89">89,90</a>]. If enlarged lymph nodes are detected, lymph node biopsy via fine needle aspiration or surgical removal of the enlarged lymph node is indicated.</p><p>Regional nodal involvement can be treated with lymph node dissection and/or RT [<a href="#rid86">86,91,92</a>]. Adjuvant RT has also been given to the nodal basin after lymph node dissection identified additional nodal disease, although the benefit is uncertain [<a href="#rid46">46</a>]. RT or completion nodal dissection can be considered for microscopic regional metastasis in periocular sites [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, taxane, and RT have been successfully used in a few patients with metastatic sebaceous carcinoma [<a href="#rid89">89,93-96</a>]. Pembrolizumab has also been successfully used in three patients with advanced/metastatic tumors without microsatellite instability (MSI) [<a href="#rid96">96-98</a>].</p><p class="headingAnchor" id="H65628368"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Local recurrence due to incomplete removal of the primary tumor is a major unfavorable determinant of prognosis. It is associated with more aggressive pathologic features and surrounding tissue invasion [<a href="#rid99">99</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a United States study using data from the National Cancer Database that included 2039 patients treated for sebaceous carcinoma between 2004 and 2017, 150 patients (7.4 percent) had a positive surgical margin [<a href="#rid100">100</a>]. Compared with patients with negative surgical margins, those with positive margins had a poorer five-year overall survival (70 versus 55 percent, respectively). Risk factors for margin positivity included head and neck location (especially the lip, ear, and periocular area), tumor size &gt;2 cm, low-volume facility, and age &gt;74 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 24 observational studies that included 1333 patients with sebaceous carcinoma of the eyelid followed up for an average of 42 months, the overall recurrence rate was 16 percent, the metastasis rate was 12 percent (with an average time to metastasis of 20.5 months), and the tumor-related mortality rate was 6 percent [<a href="#rid35">35</a>]. In the Surveillance, Epidemiology, and End Results (SEER) database, the 5- and 10-year overall survival rates were 71 and 46 percent, respectively [<a href="#rid2">2</a>]. Tumor stage T2 or worse, older age, poorly differentiated tumors, and distant (but not nodal) metastasis are unfavorable prognostic factors [<a href="#rid101">101</a>].</p><p></p><p>Patients with sebaceous carcinoma and Muir-Torre syndrome have a worse prognosis. An analysis of SEER data on over 3000 patients with sebaceous carcinoma (of whom 64 had Muir-Torre syndrome) found that the five-year, cause-specific survival rates among patients with and without Muir-Torre syndrome were 53 and 78 percent, respectively [<a href="#rid15">15</a>].</p><p>Additional prognostic factors for eyelid sebaceous carcinoma include [<a href="#rid46">46,102</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pagetoid spread</strong> – Periocular tumors showing pagetoid spread are more likely to be poorly differentiated, to be recurrent, have distant metastases, and to require exenteration [<a href="#rid67">67,103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High androgen receptor staining</strong> – Periocular tumors showing androgen receptor staining of &gt;50 percent with moderate intensity are more likely to be recurrent and develop metastases [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Programmed death receptor-1 (PD-1) expression</strong> – Tumors with PD-1 expression in tumor-infiltrating lymphocytes tend to have higher T stage and poor survival [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location</strong> – Lower eyelid or orbital extension are associated with a higher mortality rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vimentin overexpression</strong> – Vimentin overexpression in eyelid sebaceous carcinoma is associated with advanced stage, nodal metastases, pagetoid spread, and poor survival [<a href="#rid105">105</a>].</p><p></p><p class="headingAnchor" id="H4265090823"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>All patients with sebaceous carcinoma should undergo an extended follow-up after the initial treatment, every six months for three years and annually thereafter. Ultrasound nodal imaging, CT, or positron emission tomography (PET) can be arranged as indicated by initial stage for high-risk patients, especially those with periocular tumors [<a href="#rid46">46</a>]. Late relapses (pagetoid, nodal, or distant) have been reported 5 to 11 years after the excision of the primary sebaceous carcinoma [<a href="#rid91">91,92,106,107</a>].</p><p class="headingAnchor" id="H2687691975"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126519.html" rel="external">"Society guideline links: Sebaceous carcinoma and Muir-Torre syndrome"</a>.)</p><p class="headingAnchor" id="H81299093"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Sebaceous carcinoma is a rare, malignant tumor of the sebaceous glands, with an estimated incidence rate of approximately 1 to 2 per 1,000,000 per year. It most commonly occurs in the head and neck region and, particularly, on the eyelids of older individuals. Although sporadic in most cases, in a small subgroup of patients, usually younger than 60 years, sebaceous carcinoma may be a marker of Muir-Torre syndrome, a variant of the hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eyelid sebaceous carcinoma</strong> – Eyelid sebaceous carcinoma typically presents as a painless, rounded nodule, most often located on the upper eyelid  (<a class="graphic graphic_picture graphicRef70403" href="/d/graphic/70403.html" rel="external">picture 1</a>). The second most common presentation is a diffuse, unilateral thickening and inflammation of the eyelid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extraocular sebaceous carcinoma</strong> – Extraocular sebaceous carcinoma usually presents as a yellowish-tan nodule, often ulcerated, located on the head and neck in most cases or, less frequently, on the trunk or extremities. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of sebaceous carcinoma is suspected in older patients with a history of recalcitrant chalazion or unilateral blepharoconjunctivitis that does not respond to standard treatment. A lesion biopsy for histopathologic examination is required to establish the diagnosis. Immunostaining for nuclear factor XIIIa, androgen receptor, and adipophilin and perilipin may be useful to confirm the diagnosis in poorly differentiated tumors. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for Muir-Torre syndrome</strong> – Genetic testing for Muir-Torre syndrome is indicated in younger patients (&lt;60 years) who have two or more sebaceous tumors or a first sebaceous carcinoma and a personal or family history of any Lynch syndrome-related cancers (Mayo Muir-Torre syndrome risk score ≥2). (See <a class="local">'Screening for Muir-Torre syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The evaluation of patients with sebaceous carcinoma should include a careful examination of the tumor site and palpation of the regional lymph nodes. Ultrasonography or CT scan of regional lymph nodes may be indicated for patients with large or aggressive periocular tumors. Enlarged lymph nodes should be biopsied. Patients with sebaceous carcinoma of the eyelids should be referred to an ophthalmologist for slit lamp biomicroscopy and conjunctival map biopsies to evaluate for intraepithelial disease. The staging of periocular sebaceous carcinomas is performed according to the staging system for eyelid carcinoma outlined in the eighth edition of the American Joint Committee on Cancer Staging Manual  (<a class="graphic graphic_table graphicRef129566" href="/d/graphic/129566.html" rel="external">table 1</a>). (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong> – We suggest surgical excision with complete circumferential peripheral and deep margin assessment (CCPDMA) or Mohs micrographic surgery as the first-line treatment for sebaceous carcinoma of the head and neck region (including eyelid tumors) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). When Mohs surgery or CCPDMA are not available, wide local excision (WLE) with peripheral 1 cm margin down to the deep fascial plane can be an alternative approach for extraocular tumors. (See <a class="local">'Surgical treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation therapy</strong> – Radiation therapy (RT) may be used as primary treatment for both periocular and extraocular tumors in patients who are not surgical candidates and in patients who have tumors or nodal metastases that are surgically unresectable. There are limited data on the benefit of postsurgical adjuvant RT for tumors excised with positive margin or tumors with histopathologic evidence of perineural invasion. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up and prognosis</strong> – All patients with sebaceous carcinoma should undergo an extended follow-up after the initial treatment, every six months for three years and annually thereafter. For eyelid tumors, the estimated overall recurrence, metastasis, and tumor-related mortality rates over an average follow-up time of 42 months were approximately 16, 12, and 6 percent, respectively. (See <a class="local">'Follow-up'</a> above and <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg 2015; 41:1.</a></li><li><a class="nounderline abstract_t">Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009; 115:158.</a></li><li><a class="nounderline abstract_t">Muqit MM, Foot B, Walters SJ, et al. Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol 2013; 97:47.</a></li><li><a class="nounderline abstract_t">Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 2008; 113:3372.</a></li><li><a class="nounderline abstract_t">John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol 2016; 74:558.</a></li><li><a class="nounderline abstract_t">Kuzel P, Metelitsa AI, Dover DC, Salopek TG. Epidemiology of sebaceous carcinoma in Alberta, Canada, from 1988 to 2007. J Cutan Med Surg 2012; 16:417.</a></li><li><a class="nounderline abstract_t">Wu A, Rajak SN, Chiang CJ, et al. Epidemiology of cutaneous sebaceous carcinoma. Australas J Dermatol 2021; 62:57.</a></li><li><a class="nounderline abstract_t">Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol 2016; 75:1210.</a></li><li><a class="nounderline abstract_t">Jakobiec FA, Mendoza PR. Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin. Am J Ophthalmol 2014; 157:186.</a></li><li><a class="nounderline abstract_t">Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol 2009; 31:256.</a></li><li><a class="nounderline abstract_t">Mosallaei D, Lee EB, Lobl M, et al. Rare Cutaneous Malignancies in Skin of Color. Dermatol Surg 2022; 48:606.</a></li><li><a class="nounderline abstract_t">Mebazaa A, Boussofara L, Trabelsi A, et al. Undifferentiated sebaceous carcinoma: an unusual childhood cancer. Pediatr Dermatol 2007; 24:501.</a></li><li><a class="nounderline abstract_t">Omura NE, Collison DW, Perry AE, Myers LM. Sebaceous carcinoma in children. J Am Acad Dermatol 2002; 47:950.</a></li><li><a class="nounderline abstract_t">Wang F, Wang XY, Jiang X. Clinical Features and Prognosis of Young and Middle-Aged Adults With Skin Sebaceous Adenocarcinoma. Dermatol Surg 2022; 48:797.</a></li><li><a class="nounderline abstract_t">Tripathi R, Bordeaux JS. Impact of Muir-Torre Syndrome on Survival in Patients With Sebaceous Carcinoma: A SEER Population-Based Study. Dermatol Surg 2019; 45:148.</a></li><li><a class="nounderline abstract_t">Izumi M, Tang X, Chiu CS, et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol 2008; 35:704.</a></li><li><a class="nounderline abstract_t">Ishida M, Iwai M, Yoshida K, et al. Sebaceous carcinoma associated with Bowen's disease: a case report with emphasis on the pathogenesis of sebaceous carcinoma. Int J Clin Exp Pathol 2013; 6:3029.</a></li><li><a class="nounderline abstract_t">Ishida M, Okabe H. Intraepidermal sebaceous carcinoma occurring concurrently with actinic keratosis. J Cutan Pathol 2012; 39:731.</a></li><li><a class="nounderline abstract_t">Nakashima K, Adachi K, Yamasaki A, et al. Sebaceous carcinoma with actinic keratosis. Acta Derm Venereol 2010; 90:196.</a></li><li><a class="nounderline abstract_t">Ferreira I, Wiedemeyer K, Demetter P, et al. Update on the pathology, genetics and somatic landscape of sebaceous tumours. Histopathology 2020; 76:640.</a></li><li><a class="nounderline abstract_t">Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med 2014; 138:759.</a></li><li><a class="nounderline abstract_t">Harwood CA, Swale VJ, Bataille VA, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001; 116:246.</a></li><li><a class="nounderline abstract_t">Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 2011; 65:1054.</a></li><li><a class="nounderline abstract_t">North JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 2018; 9:1894.</a></li><li><a class="nounderline abstract_t">Tetzlaff MT, Curry JL, Ning J, et al. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. Clin Cancer Res 2019; 25:1280.</a></li><li><a class="nounderline abstract_t">Tetzlaff MT, Singh RR, Seviour EG, et al. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 2016; 240:84.</a></li><li><a class="nounderline abstract_t">Liau JY, Liao SL, Hsiao CH, et al. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Hum Pathol 2014; 45:533.</a></li><li><a class="nounderline abstract_t">Jayaraj P, Sen S, Sharma A, et al. Eyelid sebaceous carcinoma: a novel mutation in lymphoid enhancer-binding factor-1. Br J Dermatol 2015; 173:811.</a></li><li><a class="nounderline abstract_t">Cheng AY, Lan J, Lee CH. Impaired Wnt/beta-catenin and protein patched homolog 1 signaling in extraocular sebaceous carcinoma: A clinical and histopathological study. J Dermatol 2022; 49:600.</a></li><li><a class="nounderline abstract_t">Ito T, Hashimoto H, Tanaka Y, et al. TROP2 Expression in Sebaceous and Sweat Gland Carcinoma. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Ito T, Hashimoto H, Tanaka Y, et al. NECTIN4 expression in sebaceous and sweat gland carcinoma. Eur J Dermatol 2022; 32:181.</a></li><li><a class="nounderline abstract_t">Zhang P, Tang L, Gao H, et al. An Immunohistochemical Study of Epidermal Growth Factor Receptor in Sebaceous Carcinoma of the Eyelid: A Potential Therapeutic Target. Ophthalmic Plast Reconstr Surg 2022; 38:377.</a></li><li><a class="nounderline abstract_t">Mohsin N, Whitecar SB, Jones J, et al. Development of sebaceous carcinoma in a patient on ruxolitinib therapy. JAAD Case Rep 2022; 26:17.</a></li><li><a class="nounderline abstract_t">Sargen MR, Cahoon EK, Yu KJ, et al. Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US. JAMA Dermatol 2022; 158:414.</a></li><li><a class="nounderline abstract_t">Desiato VM, Byun YJ, Nguyen SA, et al. Sebaceous Carcinoma of the Eyelid: A Systematic Review and Meta-Analysis. Dermatol Surg 2021; 47:104.</a></li><li><a class="nounderline abstract_t">Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004; 111:2151.</a></li><li><a class="nounderline abstract_t">Shields JA, Demirci H, Marr BP, et al. Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg 2005; 21:92.</a></li><li><a class="nounderline abstract_t">Chang K, Wileman JM, Gabbard RD, et al. Isolated primary sebaceous gland carcinoma of the bulbar conjunctiva. Am J Ophthalmol Case Rep 2022; 27:101675.</a></li><li><a class="nounderline abstract_t">Kumabe A, Kawase T, Miura K, et al. Sebaceous carcinoma of the parotid gland: F-18 FDG PET/CT findings. Clin Nucl Med 2010; 35:260.</a></li><li><a class="nounderline abstract_t">Gnepp DR. My journey into the world of salivary gland sebaceous neoplasms. Head Neck Pathol 2012; 6:101.</a></li><li><a class="nounderline abstract_t">Kyriakos Saad M, Ghandour F, El Hachem G, et al. Special type breast carcinoma: Sebaceous carcinoma of the breast; A case report and review of literature. Breast J 2020; 26:2034.</a></li><li><a class="nounderline abstract_t">Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck 2012; 34:1765.</a></li><li><a class="nounderline abstract_t">Sawyer AR, McGoldrick RB, Mackey S, et al. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy? Dermatol Surg 2009; 35:704.</a></li><li><a class="nounderline abstract_t">Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol 2008; 47:276.</a></li><li><a class="nounderline abstract_t">Sarangi J, Kakkar A, Roy D, et al. Metastases to the Parotid Gland: Study from a Tertiary Care Centre. Head Neck Pathol 2022; 16:1034.</a></li><li><a class="nounderline abstract_t">Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol 2019; 20:e699.</a></li><li><a class="nounderline abstract_t">Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol 2007; 13:301.</a></li><li><a class="nounderline abstract_t">Iacobelli J, Harvey NT, Wood BA. Sebaceous lesions of the skin. Pathology 2017; 49:688.</a></li><li><a class="nounderline abstract_t">Flux K. Sebaceous Neoplasms. Surg Pathol Clin 2017; 10:367.</a></li><li><a class="nounderline abstract_t">Mulay K, White VA, Shah SJ, Honavar SG. Sebaceous carcinoma: clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor). Can J Ophthalmol 2014; 49:326.</a></li><li><a class="nounderline abstract_t">Ansai S, Takeichi H, Arase S, et al. Sebaceous carcinoma: an immunohistochemical reappraisal. Am J Dermatopathol 2011; 33:579.</a></li><li><a class="nounderline abstract_t">Plaza JA, Mackinnon A, Carrillo L, et al. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study. Am J Dermatopathol 2015; 37:809.</a></li><li><a class="nounderline abstract_t">Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol 2009; 36:613.</a></li><li><a class="nounderline abstract_t">Roberts ME, Riegert-Johnson DL, Thomas BC, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 2014; 16:711.</a></li><li><a class="nounderline abstract_t">Schon K, Rytina E, Drummond J, et al. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting. Clin Exp Dermatol 2018; 43:410.</a></li><li><a class="nounderline abstract_t">Everett JN, Raymond VM, Dandapani M, et al. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 2014; 150:1315.</a></li><li><a class="nounderline abstract_t">Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology 2010; 56:133.</a></li><li><a class="nounderline abstract_t">Ramachandran V, Tumyan G, Loya A, et al. Sebaceous Carcinoma Masquerading As Orbital Cellulitis. Cureus 2022; 14:e22288.</a></li><li class="breakAll">American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2017.</li><li class="breakAll">American Society of Clinical Oncology. Eyelid Cancer: Stages and Grades, August 2015. https://www.cancer.net/cancer-types/eyelid-cancer/stages-and-grades (Accessed on December 12, 2014).</li><li><a class="nounderline abstract_t">Ding S, Sagiv O, Guo Y, et al. Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual. Ophthalmic Plast Reconstr Surg 2019; 35:38.</a></li><li><a class="nounderline abstract_t">Sen S, Bhardwaj M, Jayaraj P, et al. Eyelid sebaceous gland carcinoma, validation of AJCC 8th edition T staging- a retrospective study from North India. Acta Ophthalmol 2023; 101:49.</a></li><li><a class="nounderline abstract_t">Morawala A, Mohamed A, Krishnamurthy A, et al. Sebaceous gland carcinoma: analysis based on the 8th edition of American Joint Cancer Committee classification. Eye (Lond) 2023; 37:714.</a></li><li><a class="nounderline abstract_t">Knackstedt T, Samie FH. Sebaceous Carcinoma: A Review of the Scientific Literature. Curr Treat Options Oncol 2017; 18:47.</a></li><li><a class="nounderline abstract_t">Ishiguro Y, Homma S, Yoshida T, et al. Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Rep 2017; 3:71.</a></li><li><a class="nounderline abstract_t">Plaza JA, Chung C, Salim S, et al. Sebaceous Carcinomas: A Clinicopathological Comparison of Ocular and Extraocular Variants. Am J Dermatopathol 2021; 43:763.</a></li><li><a class="nounderline abstract_t">Sa HS, Rubin ML, Xu S, et al. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. Br J Ophthalmol 2019; 103:980.</a></li><li><a class="nounderline abstract_t">Maloney NJ, Nguyen KA, So NA, Zaba LC. Yield of sentinel lymph node biopsy in sebaceous carcinoma and predictors of advanced disease: A retrospective analysis of the National Cancer Database. J Am Acad Dermatol 2023; 88:504.</a></li><li><a class="nounderline abstract_t">Hou JL, Killian JM, Baum CL, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg 2014; 40:241.</a></li><li><a class="nounderline abstract_t">Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg 2004; 30:1164.</a></li><li><a class="nounderline abstract_t">Su C, Nguyen KA, Bai HX, et al. Comparison of Mohs Surgery and Surgical Excision in the Treatment of Localized Sebaceous Carcinoma. Dermatol Surg 2019; 45:1125.</a></li><li><a class="nounderline abstract_t">Zhou C, Wu F, Chai P, et al. Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients. J Am Acad Dermatol 2019; 80:1608.</a></li><li><a class="nounderline abstract_t">Elias ML, Skula SR, Behbahani S, et al. Localized sebaceous carcinoma treatment: Wide local excision verses Mohs micrographic surgery. Dermatol Ther 2020; 33:e13991.</a></li><li><a class="nounderline abstract_t">Lally SE, Rao R, Shields JA, Shields CL. Comparison of posterior lamellar resection versus lumpectomy for initial management of localized tarsal conjunctival sebaceous carcinoma in 54 cases. Indian J Ophthalmol 2018; 66:1295.</a></li><li><a class="nounderline abstract_t">Conill C, Toscas I, Morilla I, Mascaró JM Jr. Radiation therapy as a curative treatment in extraocular sebaceous carcinoma. Br J Dermatol 2003; 149:441.</a></li><li><a class="nounderline abstract_t">Azad S, Choudhary V. Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid. J Cancer Res Ther 2011; 7:157.</a></li><li><a class="nounderline abstract_t">Hata M, Koike I, Maegawa J, et al. Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function. Strahlenther Onkol 2012; 188:1102.</a></li><li><a class="nounderline abstract_t">Pardo FS, Wang CC, Albert D, Stracher MA. Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1989; 17:643.</a></li><li><a class="nounderline abstract_t">Shields JA, Shields CL, Freire JE, et al. Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2. Ophthalmic Plast Reconstr Surg 2003; 19:91.</a></li><li><a class="nounderline abstract_t">Shields JA, Saktanasate J, Lally SE, et al. Sebaceous Carcinoma of the Ocular Region: The 2014 Professor Winifred Mao Lecture. Asia Pac J Ophthalmol (Phila) 2015; 4:221.</a></li><li><a class="nounderline abstract_t">Lisman RD, Jakobiec FA, Small P. Sebaceous carcinoma of the eyelids. The role of adjunctive cryotherapy in the management of conjunctival pagetoid spread. Ophthalmology 1989; 96:1021.</a></li><li><a class="nounderline abstract_t">Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010; 94:1316.</a></li><li><a class="nounderline abstract_t">Tumuluri K, Kourt G, Martin P. Mitomycin C in sebaceous gland carcinoma with pagetoid spread. Br J Ophthalmol 2004; 88:718.</a></li><li><a class="nounderline abstract_t">Shields CL, Naseripour M, Shields JA, Eagle RC Jr. Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology 2002; 109:2129.</a></li><li><a class="nounderline abstract_t">Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006; 90:819.</a></li><li><a class="nounderline abstract_t">Deo SV, Shukla NK, Singh M, et al. Locally advanced sebaceous cell carcinoma (T3) of eyelid: incidence and pattern of nodal metastases and combined modality management approach. Orbit 2012; 31:150.</a></li><li><a class="nounderline abstract_t">Verma S, Kumar N, Meel R, et al. Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study. Ocul Oncol Pathol 2021; 7:251.</a></li><li><a class="nounderline abstract_t">Woods AD, Grushchak S, Williams KM, et al. Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery. Australas J Dermatol 2022; 63:e345.</a></li><li><a class="nounderline abstract_t">Jung YH, Woo IS, Kim MY, et al. Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: Case report and literature review. Asia Pac J Clin Oncol 2016; 12:e189.</a></li><li><a class="nounderline abstract_t">Orcurto A, Gay BE, Sozzi WJ, et al. Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy. Case Rep Dermatol 2014; 6:80.</a></li><li><a class="nounderline abstract_t">Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection. JAMA Ophthalmol 2013; 131:1091.</a></li><li><a class="nounderline abstract_t">Rath S, Honavar SG, Reddy VA, et al. Sebaceous carcinoma of the eyelid metastasizing to the lacrimal sac after 5 years. Orbit 2009; 28:309.</a></li><li><a class="nounderline abstract_t">Murthy R, Honavar SG, Burman S, et al. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg 2005; 21:307.</a></li><li><a class="nounderline abstract_t">Priyadarshini O, Biswas G, Biswas S, et al. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg 2010; 26:366.</a></li><li><a class="nounderline abstract_t">Ota S, Sakamoto T, Ochiai R, et al. Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review. Case Rep Oncol 2019; 12:47.</a></li><li><a class="nounderline abstract_t">Domingo-Musibay E, Murugan P, Giubellino A, et al. Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer 2018; 6:58.</a></li><li><a class="nounderline abstract_t">Kodali S, Tipirneni E, Gibson PC, et al. Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma. Ophthalmic Plast Reconstr Surg 2018; 34:e149.</a></li><li><a class="nounderline abstract_t">Banerjee N, Hossain F, Wirtschafter E, Fathizadeh P. Pembrolizumab in the Treatment of Microsatellite Instability-High Sebaceous Carcinoma: A Case Report With Review of the Literature. JCO Precis Oncol 2020; 4:61.</a></li><li><a class="nounderline abstract_t">Hsia Y, Yeh CY, Wei YH, et al. Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival. Eye (Lond) 2019; 33:887.</a></li><li><a class="nounderline abstract_t">Maloney NJ, Aasi SZ, Hirotsu KE, et al. Positive surgical margins in sebaceous carcinoma: Risk factors and prognostic impact. J Am Acad Dermatol 2023; 89:184.</a></li><li><a class="nounderline abstract_t">Thomas WW, Fritsch VA, Lentsch EJ. Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck. Laryngoscope 2013; 123:2165.</a></li><li><a class="nounderline abstract_t">In 't Veld EH, Keizer R, Post N, et al. Outcome after treatment for sebaceous carcinoma: A multicenter study. J Surg Oncol 2022; 125:730.</a></li><li><a class="nounderline abstract_t">Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology 2001; 108:1877.</a></li><li><a class="nounderline abstract_t">Kandl TJ, Sagiv O, Curry JL, et al. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology 2018; 7:e1475874.</a></li><li><a class="nounderline abstract_t">Bhardwaj M, Sen S, Chosdol K, et al. Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma. Br J Ophthalmol 2020; 104:879.</a></li><li><a class="nounderline abstract_t">Park SJ, Wee WR, Lee JH, Kim MK. Primary sebaceous carcinoma of the corneaoscleral limbus with pagetoid recurrence. Korean J Ophthalmol 2009; 23:104.</a></li><li><a class="nounderline abstract_t">Folberg R, Whitaker DC, Tse DT, Nerad JA. Recurrent and residual sebaceous carcinoma after Mohs' excision of the primary lesion. Am J Ophthalmol 1987; 103:817.</a></li></ol></div><div id="topicVersionRevision">Topic 97893 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25521100" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sebaceous carcinoma: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988294" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A retrospective review of 1349 cases of sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117971" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18932259" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892655" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23149197" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of sebaceous carcinoma in Alberta, Canada, from 1988 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32632921" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of cutaneous sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27720512" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence and survival of sebaceous carcinoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24112633" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384066" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384892" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rare Cutaneous Malignancies in Skin of Color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958796" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Undifferentiated sebaceous carcinoma: an unusual childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451386" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sebaceous carcinoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35917259" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Features and Prognosis of Young and Middle-Aged Adults With Skin Sebaceous Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29578884" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of Muir-Torre Syndrome on Survival in Patients With Sebaceous Carcinoma: A SEER Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120764" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ten cases of sebaceous carcinoma arising in nevus sebaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24294397" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sebaceous carcinoma associated with Bowen's disease: a case report with emphasis on the pathogenesis of sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22416794" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intraepidermal sebaceous carcinoma occurring concurrently with actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20169311" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sebaceous carcinoma with actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31821583" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Update on the pathology, genetics and somatic landscape of sebaceous tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24878016" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular pathology of skin neoplasms of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180000" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21550136" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29760388" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30420449" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27287813" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440092" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25639559" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Eyelid sebaceous carcinoma: a novel mutation in lymphoid enhancer-binding factor-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35318716" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impaired Wnt/beta-catenin and protein patched homolog 1 signaling in extraocular sebaceous carcinoma: A clinical and histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35160059" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : TROP2 Expression in Sebaceous and Sweat Gland Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35866909" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : NECTIN4 expression in sebaceous and sweat gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093989" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : An Immunohistochemical Study of Epidermal Growth Factor Receptor in Sebaceous Carcinoma of the Eyelid: A Potential Therapeutic Target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35846389" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Development of sebaceous carcinoma in a patient on ruxolitinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35262623" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347004" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sebaceous Carcinoma of the Eyelid: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582067" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sebaceous carcinoma of the eyelids: personal experience with 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778660" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35966121" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Isolated primary sebaceous gland carcinoma of the bulbar conjunctiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305416" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sebaceous carcinoma of the parotid gland: F-18 FDG PET/CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430772" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : My journey into the world of salivary gland sebaceous neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32623776" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Special type breast carcinoma: Sebaceous carcinoma of the breast; A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267270" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415798" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289332" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576094" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Metastases to the Parotid Gland: Study from a Tertiary Care Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31797796" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sebaceous carcinoma: evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670585" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sebaceous neoplasia and Torre-Muir syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29078997" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sebaceous lesions of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477886" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sebaceous Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25103648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sebaceous carcinoma: clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778832" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sebaceous carcinoma: an immunohistochemical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26485238" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515040" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603434" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29333623" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006859" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055911" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35350510" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sebaceous Carcinoma Masquerading As Orbital Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35350510" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sebaceous Carcinoma Masquerading As Orbital Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35350510" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sebaceous Carcinoma Masquerading As Orbital Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29877957" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35751173" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Eyelid sebaceous gland carcinoma, validation of AJCC 8th edition T staging- a retrospective study from North India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35347292" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sebaceous gland carcinoma: analysis based on the 8th edition of American Joint Cancer Committee classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28681210" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sebaceous Carcinoma: A Review of the Scientific Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28537014" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34651592" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sebaceous Carcinomas: A Clinicopathological Comparison of Ocular and Extraocular Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30131380" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843481" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Yield of sentinel lymph node biopsy in sebaceous carcinoma and predictors of advanced disease: A retrospective analysis of the National Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24460730" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274713" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sebaceous carcinoma of the eyelid: a review of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30829780" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparison of Mohs Surgery and Surgical Excision in the Treatment of Localized Sebaceous Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30639290" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32645237" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Localized sebaceous carcinoma treatment: Wide local excision verses Mohs micrographic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30127144" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparison of posterior lamellar resection versus lumpectomy for initial management of localized tarsal conjunctival sebaceous carcinoma in 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932271" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Radiation therapy as a curative treatment in extraocular sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768703" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104519" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2777652" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644752" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147013" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sebaceous Carcinoma of the Ocular Region: The 2014 Professor Winifred Mao Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475841" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sebaceous carcinoma of the eyelids. The role of adjunctive cryotherapy in the management of conjunctival pagetoid spread.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530655" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090432" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mitomycin C in sebaceous gland carcinoma with pagetoid spread.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414427" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672325" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551364" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Locally advanced sebaceous cell carcinoma (T3) of eyelid: incidence and pattern of nodal metastases and combined modality management approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34604196" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36073830" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23981285" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748864" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23765335" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874127" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sebaceous carcinoma of the eyelid metastasizing to the lacrimal sac after 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052148" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20856079" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792644" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29914578" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29979269" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35050729" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pembrolizumab in the Treatment of Microsatellite Instability-High Sebaceous Carcinoma: A Case Report With Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31147618" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36907557" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Positive surgical margins in sebaceous carcinoma: Risk factors and prognostic impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23670399" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34990031" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Outcome after treatment for sebaceous carcinoma: A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11581065" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30228943" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940620" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19568359" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Primary sebaceous carcinoma of the corneaoscleral limbus with pagetoid recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3591880" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Recurrent and residual sebaceous carcinoma after Mohs' excision of the primary lesion.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
